Live Webinar | Operations and Other Technology
Save
Live Webinar | Operations and Other Technology
Save
Live Webinar | Patient Financial Communications
Save
Blog | Medicare Payment and Reimbursement

CMS proposes to restrict Medicare coverage of a high-profile new Alzheimer's drug

Blog | Medicare Payment and Reimbursement

CMS proposes to restrict Medicare coverage of a high-profile new Alzheimer's drug

The drug under consideration drew headlines in 2021 for both its proposed price and the process that led to its approval by the FDA.

Medicare will pay for use of a new drug to treat Alzheimer’s disease only in limited scenarios, CMS announced Jan. 11 in a highly anticipated preliminary coverage determination.

Biogen’s drug Aduhelm would be covered only for patients enrolled in approved clinical trials that are conducted in hospital outpatient settings. Coverage also would encompass related services such as PET scans.

Aduhelm, a monoclonal antibody treatment, gained attention in 2021 for both its price and the seemingly fast-tracked nature of its approval by the FDA. An FDA advisory panel had not recommended approval, saying the drug’s clinical benefits were unproven. The process that led to the final decision in June is under investigation by Congress and the HHS Office of Inspector General.

After FDA approval, Biogen established a list price of $56,000 before cutting the price in half in December following hospital pushback.

The initial price tag affected Medicare premiums, which rose by $22 for 2022. CMS said about half the increase was tied to the prospective cost of covering Aduhelm. In response to last month’s price reduction, HHS Secretary Xavier Becerra said the premium increase would be reassessed.

Aduhelm is the first monoclonal antibody-based treatment targeting amyloid for the treatment of Alzheimer’s disease. Lee Fleisher, MD, chief medical officer and director of the Center for Clinical Standards and Quality with CMS, said evidence review suggests the possibility of harmful effects from the drug. Hence the need for further evaluation through clinical trials.

“This harm may range from headaches, dizziness and falls to other potentially serious complications such as brain bleeds,” Fleisher said in a news release. “We believe that any appropriate assessment of patient health outcomes must weigh both harm and benefit before arriving at a final decision.”

The coverage determination is subject to change during a 90-day comment period.

Read the CMS memo announcing the determination and the FDA’s June 2021 announcement approving the drug, and submit comments at the Medicare coverage database.

About the Author

Nick Hut

is a senior editor with HFMA, Westchester, Ill. (nhut@hfma.org).

Sign up for a free guest account and get access to five free articles every month.

Advertisements

Related Articles | Medicare Payment and Reimbursement

Fact Sheet | Payment Reimbursement and Managed Care

Health-Related Provisions of Inflation Reduction Act of 2022 Summary

HFMA presents a detailed summary of the health-related provisions of the new Inflation Reduction Act of 2022, signed by President Biden on August 16, 2022.

Blog | Physician Payment and Reimbursment

Recent changes to E/M coding mean time-based billing could be advantageous for longer visits, study finds

Depending on patient volumes, clinics could benefit from incorporating time-based billing instead of relying on CPT coding approaches.

Fact Sheet | Payment Reimbursement and Managed Care

FY 2023 Medicare Inpatient Rehabilitation Facility Prospective Payment System Final Rule Summary

HFMA presents a detailed summary of the final rule pertaining to the Medicare inpatient rehabilitation facility prospective payment system for FY 2023.

News | Medicare Payment and Reimbursement

News Briefs: Final rule for Medicare inpatient payments brings large rate increase

As published in hfm magazine, a monthly roundup of top news for healthcare finance professionals.